- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of July 31
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 31, 2017.
Transcript
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 31.
Number 5: A recent survey of Canadian patients highlights serious concerns about automatic substitution of biosimilars for reference products.
Number 4: Biosimilar developer Coherus has moved for a stay of discovery in its BPCIA litigation over pegfilgrastim, citing the company’s need to preserve its resources.
Number 3: The FDA Reauthorization Act of 2017 was passed by the Senate on Thursday. The must-pass bill reauthorizes user fees for biosimilar applicants.
Number 2: It was a busy week for trastuzumab biosimilars, with biologics license applications filed by Amgen and Allergan as well as Celltrion and Teva.
And Number 1: Brian Lehman takes a close look at the potential impact of Merck’s launch of Renflexis at a 35% discount off the list price of the reference, Remicade, in the US marketplace.
Finally, last week, our newsletter asked you to share your thoughts on how great a discount payers are expecting for biosimilar products. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.
To sign up for our weekly newsletter or to read these articles and more, visit www.centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
